The ESG Performance Report includes our performance across our six environmental, social and governance (ESG) priority areas, and includes ESG data for current and previous years. Within the Responsible Business section of our Annual Report, we provide a summary and highlights of our progress in 2022.
Our position on
Learn more about our views and our practices across a range of access, R&D, intellectual property, health security and environment issues here.
ESG reports archive
Search our archive of responsible business reports and resources dating back to 2002.
ESG ratings performance
Detailed below is how we perform in key ESG ratings.
|External benchmarking||Current rating
|S&P Global's Corporate Sustainability Assessment||86||88||2nd in the pharmaceutical industry group; Assessment conducted annually, current score based on 2022 submission. 2023 submission score expected to be published in Q4|
|Access to Medicines Index||4.06||4.23||Led the bi-annual index since its inception in 2008; Updated bi-annually, current results from Nov 2022|
|Antimicrobial Resistance Benchmark||84%||86%||Led the bi-annual benchmark since its inception in 2018; Current ranking updated Nov 2021|
|CDP Climate change||A-||A-||Updated annually, current scores updated Dec 2022 (for supplier engagement, March 2023)|
|CDP Water security||B||B||Updated annually, current scores updated Dec 2022 (for supplier engagement, March 2023)|
|CDP Forests (palm oil)||A-||B||Updated annually, current scores updated Dec 2022 (for supplier engagement, March 2023)|
|CDP Forests (timber)||B||B||Updated annually, current scores updated Dec 2022 (for supplier engagement, March 2023)|
|CDP Supplier engagement rating||Leader||Leader||Updated annually, current scores updated Dec 2022 (for supplier engagement, March 2023)|
|Sustainalytics||16.7||18.6||1st percentile in pharma subindustry group; Lower score represents lower risk. Current ranking updated September 2023|
|MSCI||AA||AA||Last rating action date: September 2023|
|Moody's ESG solutions||62||61||2nd in the pharmaceutical sector; Current score updated August 2023|
|ISS Corporate Rating||B+||B+||Current score updated June 2023|
|FTSE4Good||Member||Member||Member since 2004, latest review in June 2023|
|ShareAction’s Workforce Disclosure Initiative||77%||75%||Current score updated Feb 2023|
Updated November 2023
We publish our charitable giving data in our Annual Report and ESG performance summary each year. We are further increasing transparency by publishing details of our individual charitable grants over £10,000 ($15,000). Details of the grants are available in the Charitable Grants report 2022 (PDF 417.1KB).
In addition to the grants of £10,000 or more declared here, GSK discloses grants to US-based non-profit organisations that foster increased understanding of scientific, clinical, and healthcare issues and contribute to improving patient care.
Trade association memberships
GSK is a member of many trade and industry associations that primarily represent pharmaceutical, consumer products and vaccine businesses at the national, regional and international levels.Trade Association Membership 2022 (PDF - 100.8KB)
Patient organisation funding
GSK also provides funding to support UK community healthcare charities through the GSK IMPACT Awards, in partnership with The King’s Fund. This annual programme recognises and promotes excellence in community healthcare, providing funding and training to help strengthen the award winners’ current management plans and support their future aspirations.